---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061530"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:31:07.657839+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q3 net loss $34.9M; cash runway into H1 2026 after Roche deal and $25M offering

## Summary
- Net loss $34.9M vs $27.3M in Q3 2022; R&D expenses $28.3M, G&A $8.7M.
- Cash & securities $183M at Sep 30, 2023; excludes $50M Roche upfront and $25M direct offering received after quarter.
- Announced interim Phase 1/2 data for MRT-2359 showing tumor reductions in MYC-driven solid tumors; RP2 dose expected Q2 2024.
- Roche collaboration to discover MGDs; $50M upfront, potential milestones >$2B plus royalties.
- Discontinued sickle cell program; MRT-6160 IND submission planned 1H 2024.

## SEC filing metadata
- accession: 0000950170-23-061530
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/0000950170-23-061530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/glue-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061530
- JSON: https://secwatch.observer/filing/0000950170-23-061530.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061530.txt

## Key facts
- Earnings Releases
  Monte Rosa Therapeutics, Inc. reported the quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $34.9 million.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss for the third quarter of 2023 was $34.9 million
  - Result: reported results
  source text: Net loss for the third quarter of 2023 was $34.9 million, compared to $27.3 million for the third quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023061530/0000950170-23-061530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.